{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:26:50Z","timestamp":1788200810281,"version":"build-2803163510"},"reference-count":37,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T00:00:00Z","timestamp":1649030400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002141","name":"Public Health England","doi-asserted-by":"publisher","award":["ODR1718_428"],"award-info":[{"award-number":["ODR1718_428"]}],"id":[{"id":"10.13039\/501100002141","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["C8162\/A27047"],"award-info":[{"award-number":["C8162\/A27047"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Cytopathology"],"published-print":{"date-parts":[[2022,7]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND<\/jats:title>\n                    <jats:p>Overcalling of abnormalities has been a concern for using cytology triage after positive high\u2010risk human papillomavirus (HPV) tests in cervical screening.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS<\/jats:title>\n                    <jats:p>The authors studied the detection of cytological and histological abnormalities at age 24 to 64 years, using data from the English HPV pilot. The pilot compared routine implementation of primary cervical screening based on cytology (N = 931,539), where HPV test results were not available before cytology reporting, with that based on HPV testing (N = 403,269), where cytology was only required after positive HPV tests.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS<\/jats:title>\n                    <jats:p>\n                      Revealed HPV positivity was associated with a higher direct referral to colposcopy after any abnormality (adjusted odds ratio [OR\n                      <jats:sub>adj<\/jats:sub>\n                      ], 1.16; 95% confidence interval [CI], 1.14\u20101.18). Laboratories with higher direct referral referred fewer persistently HPV\u2010positive women after early recall. The detection of high\u2010grade cervical intraepithelial neoplasia (CIN2+) after direct referral increased with an OR\n                      <jats:sub>adj<\/jats:sub>\n                      of 1.17 (95% CI, 1.13\u20101.20) for informed versus uninformed cytology. Generally, the positive predictive value (PPV) of colposcopy for CIN2+ remained comparable under both conditions of interpreting cytology. In women 50 to 64 years old with high\u2010grade dyskaryosis, however, the PPV increased from 71% to 83% after revealing HPV positivity (OR\n                      <jats:sub>adj<\/jats:sub>\n                      , 2.05; 95% CI, 1.43\u20102.93).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS<\/jats:title>\n                    <jats:p>Quality\u2010controlled cervical screening programs can avoid inappropriate overgrading of HPV\u2010positive cytology.;<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/cncy.22572","type":"journal-article","created":{"date-parts":[[2022,4,4]],"date-time":"2022-04-04T12:25:07Z","timestamp":1649075107000},"page":"531-541","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Cytology interpretation after a change to HPV testing in primary cervical screening: Observational study from the English pilot"],"prefix":"10.1002","volume":"130","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9597-645X","authenticated-orcid":false,"given":"Matejka","family":"Rebolj","sequence":"first","affiliation":[{"name":"Cancer Prevention Group School of Cancer and Pharmaceutical Sciences Faculty of Life Sciences and Medicine King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Mathews","sequence":"additional","affiliation":[{"name":"Cancer Prevention Group School of Cancer and Pharmaceutical Sciences Faculty of Life Sciences and Medicine King's College London  London United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Denton","sequence":"additional","affiliation":[{"name":"Severn Pathology Southmead Hospital North Bristol NHS Trust  Bristol United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the HPV Pilot Steering Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,4,4]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62218-7"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta18230"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1177\/0969141319864991"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/dju423"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqw125"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21596"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqx163"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncy.21783"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2012-0115-CP"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajog.2011.06.101"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1309\/AJCP98ENFCNOKVAE"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l240"},{"key":"e_1_2_9_14_1","unstructured":"United Kingdom Government.Guidance. Cervical screening programme: standards. Accessed July 15 2021.https:\/\/www.gov.uk\/government\/publications\/cervical\u2010screening\u2010programme\u2010standards"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33348"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-019-0547-x"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2018-053751"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2015-009915"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.3201\/eid2201.150736"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz076"},{"key":"e_1_2_9_21_1","unstructured":"Department for Communities and Local Government.The English Index of Multiple Deprivation (IMD) 2015\u2010Guidance. Accessed October 30 2018.https:\/\/assets.publishing.service.gov.uk\/government\/uploads\/system\/uploads\/attachment_data\/file\/464430\/English_Index_of_Multiple_Deprivation_2015_\u2010_Guidance.pdf"},{"key":"e_1_2_9_22_1","unstructured":"Office for National Statistics.Populations by sex single year of age and Index of Multiple Deprivation (IMD) England 2001 to 2017. Accessed October 22 2019.https:\/\/www.ons.gov.uk\/peoplepopulationandcommunity\/populationandmigration\/populationestimates\/adhocs\/009316populationsbysexsingleyearofageandindexofmultipledeprivationimdengland2001to2017"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1177\/0969141319871977"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.3310\/hta13510"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1471-0528.13462"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.09.008"},{"key":"e_1_2_9_27_1","unstructured":"Public Health England.Cervical screening: invasive cervical cancer audit 2013 to 2016. Accessed September 9 2021.https:\/\/www.gov.uk\/government\/publications\/cervical\u2010screening\u2010invasive\u2010cervical\u2010cancer\u2010audit\u20102013\u2010to\u20102016"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2011.00948.x"},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1054\/bjoc.2001.1926"},{"key":"e_1_2_9_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2010.00771.x"},{"key":"e_1_2_9_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2006.00359.x"},{"key":"e_1_2_9_32_1","unstructured":"British Association for Cytopathology.Recommended code of practice for cytology laboratories participating in the UK cervical screening programmes (2015 updated 2017). Accessed February 22 2022.http:\/\/www.britishcytology.org.uk\/resources\/BAC_Code_of_Practice2015_\u2010_2017_update.pdf"},{"key":"e_1_2_9_33_1","unstructured":"National Health Service Digital.Cervical Screening Programme England \u2010 2019\u201020. National statistics. Accessed November 29 2020.https:\/\/digital.nhs.uk\/data\u2010and\u2010information\/publications\/statistical\/cervical\u2010screening\u2010annual\/england\u2010\u2010\u20102019\u201020"},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2303.2008.00585.x"},{"key":"e_1_2_9_35_1","unstructured":"Public Health England.Guidance. Cervical screening: guidance for laboratories providing HPV testing and cytology services in the NHS Cervical Screening Programme. Updated February 4 2021. Accessed September 11 2021.https:\/\/www.gov.uk\/government\/publications\/cervical\u2010screening\u2010laboratory\u2010hpv\u2010testing\u2010and\u2010cytology\u2010services\/cervical\u2010screening\u2010guidance\u2010for\u2010laboratories\u2010providing\u2010hpv\u2010testing\u2010and\u2010cytology\u2010services\u2010in\u2010the\u2010nhs\u2010cervical\u2010screening\u2010programme"},{"key":"e_1_2_9_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70264-3"},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j504"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2015.339"}],"container-title":["Cancer Cytopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncy.22572","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncy.22572","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncy.22572","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T12:03:50Z","timestamp":1760270630000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncy.22572"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,4]]},"references-count":37,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["10.1002\/cncy.22572"],"URL":"https:\/\/doi.org\/10.1002\/cncy.22572","archive":["Portico"],"relation":{},"ISSN":["1934-662X","1934-6638"],"issn-type":[{"value":"1934-662X","type":"print"},{"value":"1934-6638","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,4]]},"assertion":[{"value":"2022-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-03-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-04-04","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}